BLOOMFIELD, N.J., Jan. 31 /PRNewswire-FirstCall/ -- Alfacell Corporation , a biopharmaceutical company focused on the discovery, development and commercialization of novel ribonuclease therapeutics for cancer, today announced the appointment of David Sidranksy M.D. as vice chairman and lead independent director. Dr. Sidransky, 46, has been a member of Alfacell’s board of directors since 2004.
“We’re delighted that the board has appointed David to this position,” said Kuslima Shogen, chairman and chief executive officer of Alfacell. “This reflects his significant contribution to the company over the past two years and his increased commitment going forward during what is a transformational year.”
About Alfacell Corporation
Alfacell Corporation is a biopharmaceutical company using proprietary ribonuclease (RNase) technology in the discovery, development and commercialization of novel therapeutics for cancer and other life-threatening diseases.
ONCONASE is a first-in-class therapeutic from Alfacell’s proprietary ribonuclease (RNase) technology platform. ONCONASE has been shown in vitro and in vivo to target tumor cells while sparing normal cells. ONCONASE is internalized by endocytosis and released into the cytosol of the cancerous cell, where it selectively degrades tRNA beyond repair. In doing so, ONCONASE inhibits protein synthesis, stops cell cycle proliferation, and induces apoptosis (programmed cell death).
In addition to the ongoing confirmatory Phase IIIb registration study in malignant mesothelioma, the company is also conducting an ONCONASE Phase I / II trial in Non-Small Cell Lung Cancer (NSCLC) and solid tumors.
For more information, please visit www.alfacell.com.
Safe Harbor
This press release includes statements that may constitute “forward- looking” statements, usually containing the words “believe,” “estimate,” “project,” “expect” or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the Company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials, the Company’s ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the Company’s periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.
Media Contact: Investor Contact: David Schull Andreas Marathovouniotis Noonan Russo Noonan Russo 212-845-4271 212-845-4253 david.schull@eurorscg.comandreas.marathis@eurorscg.com
Alfacell Corporation
CONTACT: Media: David Schull, +1-212-845-4271, david.schull@eurorscg.com;Investors: Andreas Marathovouniotis, +1-212-845-4253,andreas.marathis@eurorscg.com, both of Noonan Russo, for AlfacellCorporation
Web site: http://www.alfacell.com/
